抗艰难梭菌新药人源型单克隆抗体bezlotoxumab
发布时间：2018-11-07 14:43
【摘要】：艰难梭菌感染是医院获得性腹泻的主要病因,发生率呈上升趋势,不但是欧美国家最常见的医疗保健机构相关性感染,近年来也成为我国面临的公共卫生安全威胁之一。2016年10月21日美国食品与药品监督管理局(FDA)批准抗艰难梭菌新药bezlotoxumab上市,用于联合标准抗菌药物治疗18岁以上艰难梭菌感染患者。现对其作用机制、药动学、临床研究及安全性等做一综述。
[Abstract]:Clostridium difficulty infection is the main cause of nosocomial diarrhea, the incidence of which is on the rise. It is not only the most common health care institution related infection in Europe and America, but also the main cause of hospital acquired diarrhea. In recent years, it has also become one of the threats to public health and safety in China. On October 21, 2016, the Food and Drug Administration (FDA) approved the launch of the new drug bezlotoxumab, a new drug against Clostridium challenge. Used in combination with standard antimicrobial agents for the treatment of patients over 18 years of age with Clostridium difficulty infection. In this paper, the mechanism, pharmacokinetics, clinical research and safety are reviewed.
【作者单位】： 航天中心医院药剂科;
【分类号】：R978
本文编号：2316682
[Abstract]:Clostridium difficulty infection is the main cause of nosocomial diarrhea, the incidence of which is on the rise. It is not only the most common health care institution related infection in Europe and America, but also the main cause of hospital acquired diarrhea. In recent years, it has also become one of the threats to public health and safety in China. On October 21, 2016, the Food and Drug Administration (FDA) approved the launch of the new drug bezlotoxumab, a new drug against Clostridium challenge. Used in combination with standard antimicrobial agents for the treatment of patients over 18 years of age with Clostridium difficulty infection. In this paper, the mechanism, pharmacokinetics, clinical research and safety are reviewed.
【作者单位】： 航天中心医院药剂科;
【分类号】：R978
【相似文献】
相关期刊论文 前6条
1 李超;;前沿[J];中国处方药;2013年04期
2 叶志康;唐惠林;段京莉;翟所迪;;非达霉素与万古霉素治疗艰难梭菌感染的有效性和安全性比较:系统评价和荟萃分析(英文)[J];Journal of Chinese Pharmaceutical Sciences;2013年06期
3 肖宇博;于锋;;艰难梭菌感染的治疗新药——非达霉素[J];药学与临床研究;2012年05期
4 马培奇;;美FDA咨询委员会推荐批准非达霉素治疗艰难梭菌感染[J];上海医药;2011年05期
5 ;FDA批准抗艰难梭菌感染新药Dificid[J];齐鲁药事;2011年07期
6 ;强力霉素可预防头孢曲松相关艰难梭菌感染[J];中国社区医师;2012年23期
，本文编号：2316682
本文链接：https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2316682.html
最近更新
教材专著
